Evidence map›Paper›PMID 41413711›Full record

ArticleNPJ precision oncology2025

Short cold atmospheric plasma treatment preserves vascular quiescence in 3D tumor-stroma-endothelial models of pancreatic cancer in vitro and in ovo.

Ruben Verloy, Emma Peeters, Angela Privat-Maldonado, Sophie Rovers, Ho Wa Lau, Louize Brants, Christophe Hermans, Jorrit De Waele, Christophe Deben, Evelien Smits and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruben Verloy *Research group PLASMANT and Center of Excellence PLASMA, University of Antwerp, Antwerp, Belgium.
Emma Peeters *Research group PLASMANT and Center of Excellence PLASMA, University of Antwerp, Antwerp, Belgium. emma.peeters@uantwerpen.be.ORCID http://orcid.org/0009-0001-6119-908X
Angela Privat-MaldonadoResearch group PLASMANT and Center of Excellence PLASMA, University of Antwerp, Antwerp, Belgium.
Sophie RoversCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
Ho Wa LauCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
Louize BrantsCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
Christophe HermansCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
Jorrit De WaeleCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
Christophe DebenCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
Evelien SmitsCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
Annemie BogaertsResearch group PLASMANT and Center of Excellence PLASMA, University of Antwerp, Antwerp, Belgium.

Funding

Fonds Wetenschappelijk Onderzoek 1S85226NFonds Wetenschappelijk Onderzoek 1SD6522NUniversiteit Antwerpen FFB210293
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) features a dense desmoplastic stroma, limiting drug delivery and promoting chemoresistance. While anti-angiogenic strategies have shown limited success, underexplored pro-angiogenic approaches may improve perfusion and treatment efficacy. Cold atmospheric plasma (CAP) generates reactive oxygen and nitrogen species and demonstrates anti-cancer effects at longer treatments and pro-healing, angiogenic effects at shorter treatments. We investigated the impact of short CAP treatment on angiogenesis in PDAC using a triple co-culture spheroid model and a turkey in ovo model, mimicking the tumor microenvironment. CAP was applied via the kINPen MED for 15-60 s in vitro and 10-30 s in ovo. In vitro, CAP inhibited endothelial tube formation treatment time-dependently and reduced VEGF-A secretion, while other angiogenic factors remained unchanged. In ovo, vascularization around the tumor was slightly increased in the BH tumors, while not significantly altered within the tumors, except for a significant reduction after 30 s of CAP treatment. Additionally, a significant increase in tumor weight was observed following short CAP treatment. These findings suggest that under standard conditions, short CAP treatment preserves vascular quiescence in PDAC and may exert subtle tumor-modulating effects, highlighting the importance of treatment parameters and model complexity in CAP-based therapeutic strategies.

Identifiers

PMID41413711
PMCPMC12827977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.